View Entire Collection
By Clinical Topic
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
A promising new therapy incorporates living cells to help patients recover from acute renal failure (ARF). Normally, patients who suffer an abrupt loss of kidney function from an acute event or injury (for example, severe blood loss or toxic insult) are treated with continuous renal replacement therapy or CRRT (hemodialysis and related treatments) until the kidneys recover. The experimental renal tubule assist device (RAD) may help buy the kidneys more recovery time.
The RAD is simply a blood filter lined with cells cultivated from donor kidneys. These cells help carry out various absorptive, immunologic, metabolic, and endocrine functions the damaged kidneys can't handle and CRRT can't perform.
In a study of 58 patients with ARF, researchers found that mortality was about 50% lower in those treated with both RAD and CRRT compared with patients who received only CRRT.
Researchers, who are working to refine the RAD for wider use, say its success may foreshadow an entirely new class of cell-based and tissue-engineered therapies.
Tumlin J, et al., "Efficacy and safety of renal tubule cell therapy for acute renal failure, Journal of the American Society of Nephrology, published online ahead of print February 13, 2008.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top